{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:56:04Z","timestamp":1790722564967,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The management of metastatic prostate cancer (mPCa) has undergone revolutionary changes over the past two decades with the introduction of novel hormonal agents, chemotherapy combinations, PARP inhibitors, and radioligand therapies. This study evaluates the real-world impact of these therapeutic advances on overall survival (OS) in Germany.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed data from the German national cancer registry covering 657,499 prostate cancer cases diagnosed between 1999 and 2021. After exclusions, 54,890 patients with de novo metastatic disease (M1) were included. Primary outcome was median OS. Secondary outcomes included 3-, 5-, and 10-year survival rates. Time series analysis assessed temporal trends using augmented Dickey-Fuller tests and joinpoint regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Median OS for M1 patients improved from 31.0 months (95% CI: 29.8\u201332.2) in 1999 to 37.0 months (35.6\u201338.4) in 2019 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). This 19.4% improvement exceeded general life expectancy gains. Age-stratified analysis revealed disparate benefits: patients &lt; 70 years experienced improvement from 34.0 to 49.0 months (\u2009+\u200944.1%), while those \u2265 70 years showed minimal change (28.0 to 29.0 months, +3.6%). Three-year survival increased from 45.1% to 50.9% (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.004), with younger patients achieving 61.3% versus 44.0% for older patients by 2019. Multivariate Cox regression confirmed diagnosis year as an independent predictor (HR 0.96, 95% CI: 0.96\u20130.97,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Real-world data confirm meaningful survival improvements in metastatic prostate cancer over two decades, validating the translation of clinical trial efficacy into routine practice. However, the pronounced age-related disparity suggests potential undertreatment of elderly patients and highlights the need for age-adapted treatment strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41391-026-01092-w","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T09:45:42Z","timestamp":1771926342000},"page":"820-825","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Survival trend in metastatic prostate cancer two decades of real-world data on overall survival from Germany"],"prefix":"10.1038","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4629-0707","authenticated-orcid":false,"given":"Marcus","family":"Sondermann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Stehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Hirtsiefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktoria","family":"Menzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Buttmann-Schweiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul Wilhelm","family":"Flemming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Kraywinkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Boehm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"key":"1092_CR1","doi-asserted-by":"publisher","first-page":"351","DOI":"10.3390\/ph17030351","volume":"17","author":"A Bernal","year":"2024","unstructured":"Bernal A, Bechler A, Mohan K, Rizzino A, Mathew G. The Current Therapeutic Landscape for Metastatic Prostate Cancer. Pharmaceuticals. 2024;17:351.","journal-title":"Pharmaceuticals"},{"key":"1092_CR2","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.eururo.2023.10.011","volume":"85","author":"De Vos II","year":"2024","unstructured":"De Vos II, Remmers S, Hogenhout R, Roobol MJ. Prostate Cancer Mortality Among Elderly Men After Discontinuing Organised Screening: Long-term Results from the European Randomized Study of Screening for Prostate Cancer Rotterdam. Eur Urol. 2024;85:74\u201381.","journal-title":"Eur Urol"},{"key":"1092_CR3","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"IF Tannock","year":"2004","unstructured":"Tannock IF, De Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer. N Engl J Med. 2004;351:1502\u201312.","journal-title":"N Engl J Med"},{"key":"1092_CR4","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","volume":"16","author":"CJ Ryan","year":"2015","unstructured":"Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PFA, Sternberg CN, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16:152\u201360.","journal-title":"Lancet Oncol"},{"key":"1092_CR5","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMoa1405095","volume":"371","author":"Beer","year":"2014","unstructured":"Beer, Armstrong TM, Rathkopf DE AJ, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in Metastatic Prostate Cancer before Chemotherapy. N Engl J Med. 2014;371:424\u201333.","journal-title":"N Engl J Med"},{"key":"1092_CR6","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher HI, Fizazi K, Saad F, Taplin M-E, Sternberg CN, Miller K, et al. Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy. N Engl J Med. 2012;367:1187\u201397.","journal-title":"N Engl J Med"},{"key":"1092_CR7","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1903307","volume":"381","author":"KN Chi","year":"2019","unstructured":"Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira De Santana Gomes AJ, Given R, et al. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med. 2019;381:13\u201324.","journal-title":"N Engl J Med"},{"key":"1092_CR8","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ejca.2021.06.010","volume":"154","author":"MR Smith","year":"2021","unstructured":"Smith MR, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, et al. Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: An analysis of the phase III ARAMIS trial. Eur J Cancer. 2021;154:138\u201346.","journal-title":"Eur J Cancer"},{"key":"1092_CR9","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.euo.2020.07.001","volume":"3","author":"AH Bryce","year":"2020","unstructured":"Bryce AH, Chen YH, Liu G, Carducci MA, Jarrard DM, Garcia JA, et al. Patterns of Cancer Progression of Metastatic Hormone-sensitive Prostate Cancer in the ECOG3805 CHAARTED Trial. Eur Urol Oncol. 2020;3:717\u201324.","journal-title":"Eur Urol Oncol"},{"key":"1092_CR10","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","volume":"392","author":"CC Parker","year":"2018","unstructured":"Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet. 2018;392:2353\u201366.","journal-title":"Lancet"},{"key":"1092_CR11","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","volume":"20","author":"K Fizazi","year":"2019","unstructured":"Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2019;20:686\u2013700.","journal-title":"Lancet Oncol"},{"key":"1092_CR12","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1158\/1078-0432.CCR-21-3940","volume":"28","author":"M Hussain","year":"2022","unstructured":"Hussain M, Corcoran C, Sibilla C, Fizazi K, Saad F, Shore N, et al. Tumor Genomic Testing for >4000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib). Clin Cancer Res. 2022;28:1518\u201330.","journal-title":"Clin Cancer Res"},{"key":"1092_CR13","doi-asserted-by":"publisher","first-page":"3426","DOI":"10.1002\/cncr.35438","volume":"130","author":"MJ Morris","year":"2024","unstructured":"Morris MJ, De Bono J, Nagarajah J, Sartor O, Wei XX, Nordquist LT, et al. Correlation analyses of radiographic progression-free survival with clinical and health-related quality of life outcomes in metastatic castration-resistant prostate cancer: Analysis of the phase 3 VISION trial. Cancer. 2024;130:3426\u201335.","journal-title":"Cancer"},{"key":"1092_CR14","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","volume":"386","author":"MR Smith","year":"2022","unstructured":"Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, et al. Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. N Engl J Med. 2022;386:1132\u201342.","journal-title":"N Engl J Med"},{"key":"1092_CR15","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1056\/NEJM199912303412706","volume":"341","author":"LF Hutchins","year":"1999","unstructured":"Hutchins LF, Unger JM, Crowley JJ, Coltman CA, Albain KS. Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment Trials. N Engl J Med. 1999;341:2061\u201367.","journal-title":"N Engl J Med"},{"key":"1092_CR16","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","volume":"6","author":"R Phillips","year":"2020","unstructured":"Phillips R, Shi WY, Deek M, Radwan N, Lim SJ, Antonarakis ES, et al. Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial. JAMA Oncol. 2020;6:650.","journal-title":"JAMA Oncol"},{"key":"1092_CR17","first-page":"1251","volume":"63","author":"PJ Goebell","year":"2024","unstructured":"Goebell PJ, Cornelius F, Fernandez Milano A, Hessler S, Schulze M. Androgendeprivation als Initial- und Basistherapie beim Prostatakarzinom: Eine retrospektive Datenanalyse aus urologischen Praxen in Deutschland. Urol. 2024;63:1251\u201358.","journal-title":"Urol"},{"key":"1092_CR18","doi-asserted-by":"publisher","unstructured":"Boehm K. Ver\u00e4nderung des Gesamt\u00fcberlebens von Patienten mit Prostatakarzinom in Deutschland \u00fcber die letzten 20 Jahre. 2023. https:\/\/doi.org\/10.25646\/11017.","DOI":"10.25646\/11017"},{"key":"1092_CR19","unstructured":"\u00a7 1 BKRG Zentrum f\u00fcr Krebsregisterdaten, Begriffsbestimmung Bundeskrebsregisterdatengesetz. https:\/\/www.buzer.de\/gesetz\/8984\/a163577.htm (accessed 23 Apr 2025)."},{"key":"1092_CR20","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1093\/biomet\/42.1-2.80","volume":"42","author":"DR Cox","year":"1955","unstructured":"Cox DR, Stuart A. Some Quick Sign Tests for Trend in Location and Dispersion. Biometrika. 1955;42:80.","journal-title":"Biometrika"},{"key":"1092_CR21","doi-asserted-by":"publisher","unstructured":"Fuller WA Introduction to Statistical Time Series: Fuller\/Introduction. John Wiley & Sons, Inc.: Hoboken, NJ, USA, 1995 https:\/\/doi.org\/10.1002\/9780470316917.","DOI":"10.1002\/9780470316917"},{"key":"1092_CR22","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1002\/sim.3017","volume":"27","author":"M Czajkowski","year":"2008","unstructured":"Czajkowski M, Gill R, Rempala G. Model selection in logistic joinpoint regression with applications to analyzing cohort mortality patterns. Stat Med. 2008;27:1508\u201326.","journal-title":"Stat Med"},{"key":"1092_CR23","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/biomet\/81.3.515","volume":"81","author":"PM Grambsch","year":"1994","unstructured":"Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994;81:515\u201326.","journal-title":"Biometrika"},{"key":"1092_CR24","unstructured":"R Core Team. R:A Language and Environment for Statistical Computing. R Foundation for Statistical Computing: Vienna, Austria, 2023 https:\/\/www.R-project.org\/."},{"key":"1092_CR25","unstructured":"Sjoberg DD, Baillie M, Fruechtenicht C, Haesendonckx S, Treis T ggsurvfit: Flexible Time-to-Event Figures. 2025 https:\/\/github.com\/pharmaverse\/ggsurvfit."},{"key":"1092_CR26","doi-asserted-by":"publisher","unstructured":"Wickham H ggplot2: Elegant Graphics for Data Analysis. 2nd ed. 2016. Springer International Publishing: Imprint: Springer: Cham, 2016 https:\/\/doi.org\/10.1007\/978-3-319-24277-4.","DOI":"10.1007\/978-3-319-24277-4"},{"key":"1092_CR27","unstructured":"Kuhn M, Wickham H Tidymodels: a collection of packages for modeling and machine learning using tidyverse principles. 2020 https:\/\/www.tidymodels.org."},{"key":"1092_CR28","unstructured":"O\u2019Hara-Wild M, Hyndman R, Wang E FABLE: Forecasting Models for Tidy Time Series. 2024 https:\/\/fable.tidyverts.org."},{"key":"1092_CR29","unstructured":"Statistisches Bundesamt. Lebenserwartung von M\u00e4nnern und Frauen bei der Geburt in Deutschland laut Sterbetafeln 1871\/81 bis 2022\/2024. Statistisches Bundesamt (Destatis): Bonn, 2025 https:\/\/www.destatis.de\/DE\/Methoden\/Qualitaet\/Qualitaetsberichte\/Bevoelkerung\/sterbetafeln.html."},{"key":"1092_CR30","doi-asserted-by":"publisher","unstructured":"NCD Countdown 2030 Collaborators (ed.). Benchmarking progress in non-communicable diseases: a global analysis of cause-specific mortality from 2001 to 2019. https:\/\/doi.org\/10.1016\/S0140-6736(25)01388-1.","DOI":"10.1016\/S0140-6736(25)01388-1"},{"key":"1092_CR31","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1056\/NEJMsb1609216","volume":"375","author":"RE Sherman","year":"2016","unstructured":"Sherman RE, Anderson SA, Dal Pan GJ, Gray GW, Gross T, Hunter NL, et al. Real-World Evidence \u2014 What Is It and What Can It Tell Us?. N Engl J Med. 2016;375:2293\u201397.","journal-title":"N Engl J Med"},{"key":"1092_CR32","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1056\/NEJM198506203122504","volume":"312","author":"AR Feinstein","year":"1985","unstructured":"Feinstein AR, Sosin DM, Wells CK. The Will Rogers Phenomenon: Stage Migration and New Diagnostic Techniques as a Source of Misleading Statistics for Survival in Cancer. N Engl J Med. 1985;312:1604\u201308.","journal-title":"N Engl J Med"},{"key":"1092_CR33","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1007\/s00259-025-07431-8","volume":"53","author":"BL Heesterman","year":"2025","unstructured":"Heesterman BL, Peters M, Oprea-Lager DE, Braat AJAT, Schoots IG, Loeff CC, et al. Increased incidence of primary metastatic prostate cancer in the era of PSMA PET\/CT: a population-based analysis. Eur J Nucl Med Mol Imaging. 2025;53:350\u201361.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1092_CR34","doi-asserted-by":"publisher","first-page":"4293","DOI":"10.1200\/JCO.23.00933","volume":"41","author":"W Dale","year":"2023","unstructured":"Dale W, Klepin HD, Williams GR, Alibhai SMH, Bergerot C, Brintzenhofeszoc K, et al. Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Systemic Cancer Therapy: ASCO Guideline Update. J Clin Oncol. 2023;41:4293\u201312.","journal-title":"J Clin Oncol"},{"key":"1092_CR35","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.eururo.2016.12.025","volume":"72","author":"J-P Droz","year":"2017","unstructured":"Droz J-P, Albrand G, Gillessen S, Hughes S, Mottet N, Oudard S, et al. Management of Prostate Cancer in Elderly Patients: Recommendations of a Task Force of the International Society of Geriatric Oncology. Eur Urol. 2017;72:521\u201331.","journal-title":"Eur Urol"},{"key":"1092_CR36","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.eururo.2023.01.020","volume":"85","author":"LK Mell","year":"2024","unstructured":"Mell LK, Pugh SL, Jones CU, Nelson TJ, Zakeri K, Rose BS, et al. Effects of Androgen Deprivation Therapy on Prostate Cancer Outcomes According to Competing Event Risk: Secondary Analysis of a Phase 3 Randomised Trial. Eur Urol. 2024;85:373\u201381.","journal-title":"Eur Urol"},{"key":"1092_CR37","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.clgc.2019.07.008","volume":"17","author":"S Knipper","year":"2019","unstructured":"Knipper S, Pecoraro A, Palumbo C, Rosiello G, Luzzago S, Tian Z, et al. A 25-year Period Analysis of Other-cause Mortality in Localized Prostate Cancer. Clin Genitourin Cancer. 2019;17:395\u201301.","journal-title":"Clin Genitourin Cancer"},{"key":"1092_CR38","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1200\/JCO.2011.38.7571","volume":"30","author":"CM Booth","year":"2012","unstructured":"Booth CM, Eisenhauer EA. Progression-Free Survival: Meaningful or Simply Measurable?. J Clin Oncol. 2012;30:1030\u201333.","journal-title":"J Clin Oncol"},{"key":"1092_CR39","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1200\/JCO.2018.78.8687","volume":"36","author":"SG Mohile","year":"2018","unstructured":"Mohile SG, Dale W, Somerfield MR, Schonberg MA, Boyd CM, Burhenn PS, et al. Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology. J Clin Oncol. 2018;36:2326\u201347.","journal-title":"J Clin Oncol"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01092-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01092-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01092-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:00:18Z","timestamp":1790719218000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01092-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,24]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1092"],"URL":"https:\/\/doi.org\/10.1038\/s41391-026-01092-w","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,24]]},"assertion":[{"value":"8 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Christian Thomas reports consulting fees from Astellas, Janssen, Bayer, and MSD; payment or honoraria for lectures, presentations, speakers\u2019 bureaus from Astellas, Janssen, Bayer, and MSD; support for attending meetings and\/or travel from Janssen and Ipsen; and serves as a board member of the German Society of Urology. Katharina Boehm receives consulting fees from MSD and Astellas, as well as travel funding by Janssen.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All methods were performed in accordance with the Declaration of Helsinki, guidelines, and regulations for medical research involving human subjects. This study received ethical approval from the scientific board of the German Centre for Cancer Registry Data at the Robert Koch Institute. No further ethical approval was needed. Informed consent is obtained by governmental regulation regarding legislation on cancer registration.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}